Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up – What’s Next?

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) gapped up before the market opened on Monday . The stock had previously closed at $9.64, but opened at $9.98. Gyre Therapeutics shares last traded at $9.79, with a volume of 25,129 shares trading hands.

Gyre Therapeutics Stock Performance

The company’s fifty day simple moving average is $12.97 and its two-hundred day simple moving average is $12.60.

Institutional Investors Weigh In On Gyre Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC increased its holdings in Gyre Therapeutics by 16.9% during the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after purchasing an additional 43,840 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Gyre Therapeutics by 392.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after buying an additional 90,557 shares in the last quarter. State Street Corp raised its position in Gyre Therapeutics by 8.8% in the 3rd quarter. State Street Corp now owns 104,490 shares of the company’s stock valued at $1,310,000 after buying an additional 8,412 shares during the last quarter. Advantage Alpha Capital Partners LP bought a new position in Gyre Therapeutics during the 3rd quarter valued at $334,000. Finally, WINTON GROUP Ltd purchased a new position in Gyre Therapeutics during the 2nd quarter worth $220,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.